期刊
BIOTECHNOLOGY JOURNAL
卷 9, 期 3, 页码 316-325出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201200383
关键词
Avermectins; Chassis; Precursor supply; Streptomyces avermitilis; Synthetic biology
资金
- National Program on Key Basic Research Project (973 program) [2013CB734000, 2012CB721006]
- National Natural Science Foundation of China [31100075, 81102362, 31170095, 31000004]
- CAS Pillar Program [XDA04074000]
- Ministry of Science and Technology of China [2011ZX11102-011-11]
- Conacyt Mexico [177568]
- National Distinguished Young Scholar Program in China
Natural products are still key sources of current clinical drugs and innovative therapeutic agents. Since wild-type microorganisms only produce natural products in very small quantities, yields of production strains need to be improved by breaking down the precise genetic and biochemical circuitry. Herein, we use avermectins as an example of production improvement and chemical structure diversification by synthetic biology. Avermectins are macrocyclic lactones produced by Streptomyces avermitilis and are well known and widely used for antiparasitic therapy. Given the importance of this molecule and its derivatives, many efforts and strategies were employed to improve avermectin production and generate new active analogues. This review describes the current status of synthetic strategies successfully applied for developing natural-product-producing strains and discusses future prospects for the application of enhanced avermectin production.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据